Skip to main content

Table 4 Participants’ characteristics/results of lung function, exercise testing, muscle function and muscle metabolism assessment in a subgroup performing a high-intensity, high-frequency constant load test to fatigue

From: Size-adjusted muscle power and muscle metabolism in patients with cystic fibrosis are equal to healthy controls – a case control study

Subgroup

Patients with CF n = 5

Healthy controls n = 10

Female (n/[%])

1 [20%]

6 [60%]

Anthropometric data

 Age (years)

23.6 ± 10.1 (13–40)

25.5 ± 4.0 (23–35)

 Height (cm)

170.0 ± 14.1 (153–185)

173.5 ± 8.6 (160–187)

 Weight (kg)

56.5 ± 15.4 (36.0–78.8)

67.8 ± 12.1 (52.0–94.0)

 Cross-sectional area M. quadriceps (cm3)

59.4 ± 7.5 (48–69)

58.1 ± 10.1 (46–71)

Lung function

 FEV1%pred

74.0 ± 13.2 (58.8–90.1)

101.4 ± 17.3 (77.2–123.6) **

 FVC%pred

86.9 ± 11.0 (75.4–101)

98.3 ± 14.0 (77.2–111-9)

Incremental exercise test (Godfrey)

 VO2 peak (%pred)

77.2 ± 9.5 (87.4–102.1)

117.7 ± 11.1 (106.0–136-0) ***

Wingate anaerobic test

 Peak power (Watt)

560 ± 182 (379–8599

714 ± 215 (480–1145)

 Mean power (Watt)

408 ± 136 (266–589)

465 ± 153 (295–748)

 Power drop (Watt)

12.2 ± 4.4 (5.3–14.4)

8.4 ± 3.5 (7.6–20.6)

MRI spectroscopy - high-intensity knee-extension protocol

 Maximal load (kg)

7.9 ± 2.0 (4.5–11)

9.1 ± 2.5 (5–11)

 Exercise time (sec)

135 ± 78 (99–156)

150 ± 51 (98–172)

 Pi/PCr rest

0.16 ± 0.04 (0.09–0.16)

0.14 ± 0.03 (0.10–0.16)

 Pi/PCr maximum

0.85 ± 0.45 (0.58–1.64)

0.96 ± 0.36 (0.42–1.44)

 Pi/PCr recovery

0.15 ± 0.09 (0.09–0.13)

0.12 ± 0.06 (0.03–0.22)

 pH rest

7.02 ± 0.02 (7.00–7.05)

7.03 ± 0.03 (6.99–7.02)

 pH maximum

7.01 ± 0.05 (6.98–7.11)

7.01 ± 0.15 (6.81–7.25)

 pH recovery

6.91 ± 0.17 (6.61–7.06)

6.96 ± 0.10 (6.82–7.11)

  1. All parameters are reported as mean ± standard deviation; differences between participants with and without CF were calculated using Student’s t-test. Significant data is marked by ***p < 0.001, ** p < 0.01